Xilio TherapeuticsXLO
13F holders, Q2 2024 (June 30)At the end of Q2 2024, 32 institutions reported holding Xilio Therapeutics Inc. (XLO) in their 13F filings, up 1 from Q1 2024. 7 opened new positions and 6 sold out. The largest holders were Bain Capital Life Sciences Investors, LLC ($3.6M), Rock Springs Capital Management LP ($2.8M) and Takeda Pharmaceutical Co. Ltd. ($1.4M). 2 famous investors held it, including Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio) and Israel Englander (0.0% of Millennium Management's portfolio).
- Company
- Xilio Therapeutics Inc.
- CUSIP
- 98422T100
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 7 | $116K |
| Exits | 6 | $1.2M |
All 13F filers, Q1 2024 → Q2 2024: 3,779,705 shares bought and 1,741,685 shares sold, net +2,038,020 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 32 holders
| Bain Capital Life Sciences Investors, LLC | 0.39% | Add +34.9% | 3,785,450 | $3.6M |
| Rock Springs Capital Management LP | 0.09% | Add +108.5% | 3,003,259 | $2.8M |
| Takeda Pharmaceutical Co. Ltd. | 0.60% | No change | 1,475,121 | $1.4M |
| RiverVest Venture Management LLC | 20.01% | No change | 1,441,444 | $1.4M |
| FMR LLC | 0.00% | Reduce -26.8% | 1,395,853 | $1.3M |
| Morgan Stanley | 0.00% | Add +401.4% | 1,112,740 | $1.1M |
| Vanguard Group Inc. | 0.00% | No change | 902,531 | $855K |
| Renaissance Technologies | 0.00% | Add +18.3% | 295,000 | $280K |
| Balyasny Asset Management L.P. | 0.00% | Reduce -19.5% | 272,486 | $258K |
| FIL Ltd | 0.00% | No change | 218,705 | $207K |
| Geode Capital Management, LLC | 0.00% | Add +115.6% | 182,855 | $173K |
| Bridgeway Capital Management, LLC | 0.00% | No change | 71,081 | $67K |
| BlackRock Inc. | 0.00% | Add +46.4% | 66,418 | $63K |
| State Street Corp. | 0.00% | Add +176.6% | 43,390 | $41K |
| SevenBridge Financial Group, LLC | 0.01% | Add +32.3% | 41,000 | $37K |
| Northern Trust Corp. | 0.00% | Add +120.3% | 39,208 | $37K |
| Raymond James & Associates | 0.00% | New | 38,825 | $37K |
| XTX Topco Ltd | 0.00% | New | 33,289 | $32K |
| Avantax Planning Partners, Inc. | 0.00% | New | 25,000 | $24K |
| Two Sigma Securities, LLC | 0.00% | New | 13,271 | $13K |
| Millennium Management | 0.00% | Reduce -82.6% | 12,205 | $12K |
| Charles Schwab Investment Management Inc. | 0.00% | No change | 11,925 | $11K |
| Dunhill Financial, LLC | 0.01% | No change | 10,274 | $10K |
| Pinnacle Financial Group, LLC / IL | 0.00% | New | 10,000 | $9K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -62.3% | 4,207 | $4K |
| ADAR1 Capital Management, LLC | 0.00% | New | 1,500 | $1K |
| Key Financial Inc | 0.00% | No change | 830 | $786 |
| Bank of America Corp. | 0.00% | New | 692 | $656 |
| UBS Group AG | 0.00% | No change | 201 | $191 |
| JPMorgan Chase & Co. | 0.00% | Reduce -97.8% | 59 | $56 |
| Qube Research & Technologies Ltd | 0.00% | No change | 4 | $4 |
| Royal Bank of Canada | 0.00% | Reduce -31.3% | 366 | $0 |
"% of holder's portfolio" is XLO's weight in each manager's 13F, not the share of Xilio Therapeutics Inc. the manager owns.